



GAP 2 PROSTATE CANCER ADVANCED IMAGING INITIATIVE OUTCOMES FROM MOVEMBER'S GLOBAL ACTION PLAN

WHY WE NEED TO IMPROVE **IMAGING TECHNIQUES**

for men whose cancer is limited to the prostate area is almost

The 5-year survival rate

But if the cancer has already spread, it drops to only 31%





At the time of diagnosis,

1 IN 3 men's cancer has already spread beyond the prostate bed and will require more intense treatment.

After initial treatment.

1 IN 4 men's cancer returns within 10 years of initial treatment. Earlier detection means men can be offered additional treatment to prevent the disease from progressing further.

More accurate imaging allows better and earlier decisions around men's clinical management.



Positron Emission Tomography (PET)

imaging reveals precious information on both the activity and location of cancerous cells. Very small amounts of radioactive tracer binds to the targeted cells and light up, even when the cells are too small to detect via conventional scanning methods.





Publications regarded



led to an additional in leverage fundina



contributed to the

FDA approved **PET imaging tracer**

with 1 more approval expected in 2021



Academic investigation

Clinical validation

Pending regulatory approval

Regulatory approved

Commercially available

Research Translation Pathway

¹¹C-CHOLINE VS 68GA-PSMA **COMPARATIVE STUDY**

ROJECT

N

#

0

The **PROPS study** compared the performance of the two radiotracers in detecting tumours in men whose cancer returned after initial treatment.

The results showed that ⁶⁸Ga-PSMA was able to detect twice the number of prostate cancer tumours compared to "C-Choline.

This has led to a change in clinical management for 63% of men.

In one other Movember project - the proPSMA study - PET imaging with ⁶⁸Ga-PSMA PET imaging was shown to be almost one third more accurate than standard imaging (CT and bone scan).

¹⁸F-DCFPyL RADIOTRACER DEVELOPMENT

The team worked on the initial development of ¹⁸F-DCFPyL radiotracer, which was successfully licensed to Progenic Pharmaceuticals for subsequent development and commercialisation.

It has been studied in two large clinical trials - OSPREY and CONDOR - and was shown to accurately detect prostate cancer tumours both at initial diagnostic as well as disease recurrence.

Based on the positive outcomes from both clinical trials, this radiotracer is expected to receive FDA approval in 2021.



3

#

PROJECT

Leveraging the original GAP2 dataset in ¹⁸F-FDHT, the team received a Challenge Award in 2019 from the Prostate Cancer Foundation to transform this project into a comparative study between ¹⁸F-FDHT and ¹⁸F-PSMA.

As the only active project within GAP2, this project will compare the prognostic value of these two radiotracers in men with advanced prostate cancer treated with androgen receptor-directed therapy.

18F-FLUCICLOVINE RADIOTRACER DEVELOPMENT

The research team worked on the initial development of this radiotracer. It was then passed onto Blue Earth Diagnostic early on for subsequent development and commercialisation.

Also known as Axumin®, it became the first PET imaging radiotracer approved by the FDA in 2016 to detect prostate cancer in men with elevated level of PSA after initial treatment.



THANK YOU

The GAP 2 program was funded thanks to the generosity of the Movember community.

